Publications

Musselman K, Glynn S, Mosquera JMiguel, Elemento O, Sboner A, Beltran H, Holcomb K.  2019.  Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma.. Gynecol Oncol Rep. 28:54-57.

Van Emmenis L, Ku S-Y, Gayvert K, Branch JR, Brady NJ, Basu S, Russell M, Cyrta J, Vosoughi A, Sailer V et al..  2023.  The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.. Cancer Res Commun. 3(8):1447-1459.

Davis M, Martini R, Newman L, Elemento O, White J, Verma A, Datta I, Adrianto I, Chen Y, Gardner K et al..  2020.  Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations.. Cancers (Basel). 12(5)

Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JYun Helen, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N et al..  2012.  Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.. Proc Natl Acad Sci U S A. 109(17):6686-91.

Bovonratwet P, Kulm S, Kolin DA, Song J, Morse KW, Cunningham ME, Albert TJ, Sandhu HS, Kim HJo, Iyer S et al..  2023.  Identification of Novel Genetic Markers for the Risk of Spinal Pathologies: A Genome-Wide Association Study of 2 Biobanks.. J Bone Joint Surg Am. 105(11):830-838.

Durrans A, Gao D, Gupta R, Fischer KR, Choi H, Rayes TEl, Ryu S, Nasar A, Spinelli CF, Andrews W et al..  2015.  Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC.. PLoS One. 10(6):e0129123.

Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC.  2018.  Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.. Cancer Discov. 8(3):354-369.

Elemento O, Lefranc MPaule.  2003.  IMGT/PhyloGene: an on-line tool for comparative analysis of immunoglobulin and T cell receptor genes.. Dev Comp Immunol. 27(9):763-79.

Markowitz GJ, Havel LS, Crowley MJp, Ban Y, Lee SB, Thalappillil JS, Narula N, Bhinder B, Elemento O, Wong STc et al..  2018.  Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.. JCI Insight. 3(13)

Bhinder B, Ferguson A, Sigouros M, Uppal M, Elsaeed AG, Bareja R, Alnajar H, Eng KWha, Conteduca V, Sboner A et al..  2023.  Immunogenomic Landscape of Neuroendocrine Prostate Cancer.. Clin Cancer Res. 29(15):2933-2943.

Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):3819.

de Martino M, Zhuang D, Klatte T, Rieken M, Rouprêt M, Xylinas E, Clozel T, Krzywinski M, Elemento O, Shariat SF.  2014.  Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.. Cancer Biol Ther. 15(9):1239-47.

Buqué A, Bloy N, Petroni G, Jiménez-Cortegana C, Sato A, Iribarren C, Yamazaki T, Galassi C, Hensler M, Bhinder B et al..  2025.  Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor-positive mammary carcinogenesis.. J Natl Cancer Inst. 117(5):934-947.

Cuppen E, Elemento O, Rosenquist R, Nikic S, IJzerman M, Zaleski IDurand, Frederix G, Levin L-Å, Mullighan CG, Buettner R et al..  2022.  Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care.. JCO Precis Oncol. 6:e2200245.

Assaad MAl, Gundem G, Liechty B, Sboner A, Medina J, Papaemmanuil E, Sternberg CN, Marks A, Souweidane MM, Greenfield JP et al..  2023.  The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer.. Cold Spring Harb Mol Case Stud. 9(4)

Zoughbi WAl, Kim D, Alperstein SAnn, Ohara K, Manohar J, Greco N, Khani F, Robinson BD, Rao RA, Elemento O et al..  2021.  Incorporating cytologic adequacy assessment into precision oncology workflow using telepathology: An institutional experience.. Cancer Cytopathol.

Chatterjee SS, Linares JF, Cid-Diaz T, Duran A, Khan MImran K, Osrodek M, Brady NJ, Reina-Campos M, Marzio A, Venkadakrishnan VBalaji et al..  2024.  Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer.. Nat Commun. 15(1):9755.

Giannopoulou EG, Elemento O.  2013.  Inferring chromatin-bound protein complexes from genome-wide binding assays.. Genome Res. 23(8):1295-306.

Argueta LB, Lacko LA, Bram Y, Tada T, Carrau L, Rendeiro AFigueiredo, Zhang T, Uhl S, Lubor BC, Chandar V et al..  2022.  Inflammatory responses in the placenta upon SARS-CoV-2 infection late in pregnancy.. iScience. 25(5):104223.

Romanel A, Garritano S, Stringa B, Blattner M, Dalfovo D, Chakravarty D, Soong D, Cotter KA, Petris G, Dhingra P et al..  2017.  Inherited determinants of early recurrent somatic mutations in prostate cancer.. Nat Commun. 8(1):48.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.. N Engl J Med. 375(5):443-53.

Schwarz E, Benner B, Wesolowski R, Quiroga D, Good L, Sun SH, Savardekar H, Li J, Jung KJoo, Duggan MC et al..  2024.  Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.. JCI Insight. 9(21)

Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, Cerchietti L, Vahdat L, Brown KA, Andreopoulou E et al..  2020.  Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.. Cell Rep. 30(3):755-770.e6.

Raman R, Villefranc JA, Ullmann TM, Thiesmeyer J, Anelli V, Yao J, Hurley JR, Pauli C, Bareja R, Eng KWha et al..  2022.  Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer.. J Exp Med. 219(6)

Liu H, Paddock MN, Wang H, Murphy CJ, Geck RC, Navarro AJ, Wulf GM, Elemento O, Haucke V, Cantley LC et al..  2020.  The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.. Cancer Discov. 10(8):1226-1239.